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ABSTRACT
Objective: To examine if there is widespread inflammation in the brain of patients with chronic
lymphocytic inflammation with pontine perivascular enhancement responsive to steroids
(CLIPPERS) syndrome by using histology and ultra-high-field MRI at 7.0T.
Methods: We performed a detailed neuropathologic examination in 4 cases, including 1 autopsy
case, and studied 2 additional patients byMRI at 7.0T to examine (1) extension of inflammation to
areas appearing normal on 3.0TMRI, (2) potential advantages of 7.0T MRI compared to 3.0T MRI
in reflecting widespread inflammation, perivascular pathology, and axonal damage, and (3) the
possibility of lymphoma.
Results: In the autopsy case, perivascular inflammation dominated by CD41 T cells was not only
detected in the brainstem and cerebellum but also in brain areas with normal appearance on 3.0T
MRI, including supratentorial regions and cranial nerve roots. There was no evidence of lymphoma
in any of the 4 patients. The 7.0TMRI in clinical remission also revealed supratentorial lesions and
perivascular pathology in vivo with contrast-enhancing lesions centered around a small venous
vessel. Ultra-high-field MRI at 7.0T disclosed prominent T1 hypointensities in the brainstem,
which were not seen on 3.0T MRI. This corresponded to neuropathologic detection of axonal
injury in the autopsy case.
Conclusion: Our findings suggest more widespread perivascular inflammation and postinflamma-
tory axonal injury in patients with CLIPPERS. Neurol Neuroimmunol Neuroinflamm 2016;3:e226; doi:
10.1212/NXI.0000000000000226
GLOSSARY
CLIPPERS 5 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids; H&E 5
hematoxylin & eosin; mRS 5 modified Rankin Scale; MS 5 multiple sclerosis; T2*W 5 T2*-weighted; TE 5 echo time;
TR 5 repetition time; T1W MPRAGE 5 T1-weighted magnetization-prepared rapid gradient echo; SWI 5 susceptibility-
weighted imaging; VIBE 5 volumetric interpolated brain examination.
Features of chronic lymphocytic inflammation with pontine perivascular enhancement respon-
sive to steroids (CLIPPERS)1 include subacute brainstem symptoms, MRI appearance with
multiple punctate or curvilinear gadolinium enhancements, and a clear response to immuno-
suppressive treatment.1–3 Since the original case series, several cases have been described, some of
which suggest that the CLIPPERSMRI appearance can be seen in other inflammatory disorders,
such as primary angiitis of the CNS4 or multiple sclerosis (MS).5 Recently, cases have been
reported with development of lymphoma after the initial diagnosis of CLIPPERS.6–8
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While former neuropathologic examina-
tions have revealed a predominant perivascular
CD31 T-cell inflammation in the affected
regions, these studies were confined to biopsy
specimens and thus could not analyze the
extent of inflammation in other brain areas.
Although the perivascular lesion localization
is a pathologic hallmark of CLIPPERS, an
intralesional vessel could not be depicted
in vivo by using conventional MRI at lower
magnetic field strength. Gaining from increased
susceptibility effects and spatial resolution,
ultra-high-field MRI at 7.0T improved the
detection of both vascular abnormalities9–13
and structural CNS damage14–16 and may thus
be a promising technique to visualize perivas-
cular inflammation and tissue destruction in
CLIPPERS.
We report results of a neuropathologic
examination of an autopsy case to study the
pathology of brain regions with normal
appearance on 3.0T MRI. We also investi-
gated supratentorial lesions in 2 patients with
CLIPPERS in vivo by 7.0T MRI.
METHODS Standard approvals, registrations, and patients.
Biopsy samples were obtained for diagnostic purposes. Pathologic
samples (biopsy and autopsy) were retrospectively analyzed. The pro-
spective MRI part of the study was approved by the local ethics com-
mittee (EA 1/054/09). Written consent was obtained from all
participants prior to examination.
Description of autopsy case (patient 1). Patient 1 is a 62-
year old man who was admitted in 2008 because of subacute
onset diplopia, dysphagia, and balance problems (table).
Neurologic examination revealed gaze-evoked nystagmus,
diplopia, limb and gait ataxia, and moderate postural tremor of
the upper extremities. MRI showed patchy T2 signal
hyperintensities in the brainstem and cerebellar peduncles with
punctate gadolinium enhancements (figure 1). Three lumbar
punctures during the disease course revealed mild lymphocytic
pleocytosis (37, 17, and 15 leukocytes per microliter) but no
oligoclonal bands. MRI angiography and whole-body FDG-
PET-CT were normal. There was no evidence of malignant
cells and viral examinations of the CSF for herpesviruses
were negative. Search for onconeural antibodies, antinuclear
antibodies, antineutrophil cytoplasmic antibodies, anti-SSA, anti-
SSB, anticardiolipin, elevated angiotensin-converting enzyme in
sera and CSF, and tuberculosis tests were normal. The patient
recovered on high-dose steroid treatment, but relapsed after its
withdrawal. Brainstem biopsy showed perivascular CD41 T-cell
infiltrations. There was no evidence of lymphoma or vessel
destruction. Staining for herpes simplex virus 1 and 2 were
normal. The patient responded to steroid treatment, but then
had a fatal brainstem hemorrhage. In 2014, the history and
initial brain biopsy specimens were re-evaluated and CLIPPERS
syndrome was diagnosed.
Description of the 3 cases with brainstem biopsy
(patients 2–4). The clinical course, MRI data, and follow-up
of the 3 patients have been recently described elsewhere.17
Patient 2 is a 23-year-old man who developed subacute
nystagmus and gait ataxia (table). He was treated with
methylprednisolone and azathioprine, but had 6 relapses in 14
years with gradual worsening of cerebellar dysarthria and gait
ataxia. CSF showed mild pleocytosis and oligoclonal bands.
Brain biopsy indicated perivascular inflammatory infiltrates
predominantly composed of CD31 T cells. MRI showed
punctate gadolinium enhancement in the pons. No systemic
autoantibodies were found. At present, the patient is
ambulatory (modified Rankin Scale [mRS] 2).17 Patient 3 is
a 58-year-old woman who developed subacute gait ataxia,
dysarthria, and paresthesia of the face, hands, and feet (table).
She had 4 relapses in 6 years. CSF showed mild lymphocytosis
and no oligoclonal bands. Brain biopsy indicated parenchymal
and perivascular inflammatory infiltrates predominantly
composed of CD31 T cells. MRI revealed multiple punctate
gadolinium enhancement in the pons and brachium pontis. No
systemic autoantibodies were found. At present, the patient is
severely dysarthric, wheelchair-bound, and has mild involuntary
movements (mRS 4).17 Patient 4 is a 42-year-old man who
Table Demographics, clinical symptoms, treatment, and timing of MRI or neuropathologic investigations of patients in this study
Patients Sex/age, y Time and symptoms at diagnosis
Clinical
state at
MRI
Treatment at
biopsy
Treatment at
MRI
Time between symptom onset
and MRI/autopsy/biopsy Ref3.0T 7.0T
Patient 1 (autopsy
and 3.0T MRI)
M/62 2008: Diplopia, dysphagia, dysarthria,
ataxia
Rel NA Prednisone Prednisone 3.0T MRI: 1 week; autopsy:
3 mo
NA
Patient 2 (biopsy 1) M/23 1999: Nystagmus, ataxia, anorexia NA NA None NA Biopsy: 27 mo 17
Patient 3 (biopsy 2) F/58 2007: Ataxia, dysarthria, paresthesia
(hands and feet)
NA NA Prednisone;
methotrexate
NA Biopsy: 15 mo 17
Patient 4 (biopsy 3) M/42 2010: Tetraspasticity, proximal
paraparesis, dysarthria, diplopia, ataxia
NA NA Prednisone NA Biopsy: 5 mo 17
Patient 5 (3.0T and
7.0T MRI)
F/48 2013: Hemiparesthesia, double vision,
gait instability, dysarthria, facial pain
Rem Rem NA Prednisone;
methotrexate
7.0T MRI: 13 mo NA
Patient 6 (3.0T and
7.0T MRI)
F/73 2010: Fatigue, diplopia, ataxia, dysarthria Rem Rem NA Prednisone;
methotrexate
3.0T MRI: 49 mo; 7.0T MRI:
49 mo
18
Abbreviations: NA 5 not applicable; Rel 5 Relapse; Rem 5 Remission.
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developed subacute dysarthria, horizontal nystagmus, diplopia,
jerky eye movements, ataxia, tetraspasticity, and paraparesis
(table). CSF showed mild pleocytosis and no persisting
oligoclonal bands. Brain biopsy indicated parenchymal and
perivascular inflammatory infiltrates predominantly composed of
CD31 T cells. MRI showed multiple punctate gadolinium-
enhancing lesions in the cerebellum, brainstem, and midbrain.
No systemic autoantibodies were found. Symptoms and MRI
lesions rapidly responded to methylprednisolone. He was treated
with methotrexate and azathioprine, and had only a single relapse
Figure 1 Neuropathologic examination of brain areas with normal MRI appearance and with gadolinium
enhancement (patient 1)
(A) MRI of patient 1 shows T2-weighted hyperintensities in brainstem and cerebellar peduncles with similar pattern of ga-
dolinium enhancement. Arrows depict areas used for immunohistochemical stainings for CD45, CD3, CD4, CD8, and CD20
in brainstem (B–F) and cerebellum (L–P) with punctate gadolinium enhancements and parietal (G–K) and insular cortex (Q–U)
with normal MRI appearance. We found prominent CD41 T-cell infiltration in the brainstem (D) and cerebellum (N) but also in
insular cortex (S) and parietal cortex (I). The magnitude of infiltration shows a gradient with less infiltration with greater
distance from the brainstem. Similarly, we found less infiltration of CD81 T cells (E, J, O, and T) and only a very limited
number of CD201 B cells (F, K, P, and U) with a similar gradient in cell numbers and degree of infiltration into the tissue.
Hematoxylin & eosin staining reveals inflammation also in cranial nerve roots from the brainstem (V and W). Magnification
53 (B and F) (V and W), 103 (G–U). Scale bar: 200 mm (B–F), 100 mm (G–U), 200 mm (V, W).
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during the follow-up period of 19 months (mRS 2). The patient
committed suicide.17
Patients examined by 7T MRI (patients 5 and 6). Two
additional patients with CLIPPERS were included in the 7.0T
MRI study.
Patient 5 is a 48-year-old woman who developed subacute
numbness in the left half of her body, double vision, gait insta-
bility, dysarthria, facial pain, numbness of the oral cavity, and
fatigue over a period of 2 weeks in September 2013 (table).
During the weeks before the onset of these symptoms, she had
noted frontal headaches. The patient was admitted to another
hospital in October 2013, where a cranial 1.5T MRI demon-
strated multiple small T2 hyperintense lesions with punctate
and curvilinear contrast enhancement in the pons and cerebel-
lum, and a bigger right cerebellar lesion. As this case has not
been published before, the brain MRI findings of this patient
are shown in figure e-1 at Neurology.org/nn. A spinal cord
MRI demonstrated a small longitudinal contrast-enhancing
lesion in the cervical cord. The cerebellar lesion was biopsied
in October 2013. Histologic analysis revealed cerebellitis with
prominent CD41 T-cellular infiltrates, compatible with
CLIPPERS syndrome. There were no signs of lymphoma.
Antinuclear antibodies, antibodies to extractable nuclear anti-
gens, and antineutrophil cytoplasmic antibodies as well as anti-
bodies to aquaporin-4 were negative. She was initially treated
with high-dose IV methylprednisolone (1 g/day for 3 days
followed by 1 g/day for 5 days) and subsequently with oral
prednisolone (starting dose 25 mg/day with a subsequent taper
to 5 mg/day) and azathioprine (3 3 50 mg), which was
changed to methotrexate in May 2014, when a cranial MRI
demonstrated constant to minimally progressive CLIPPERS
lesions. At the time of the 7.0T MRI examination, she was
treated with prednisolone (5 mg daily) and methotrexate (15
mg weekly), and had residual facial paresthesiae but no clinical
signs of new disease activity.
Patient 6 is a 73-year-old woman who was diagnosed with
CLIPPERS in October 2010 and whose clinical and paraclinical
details were previously reported in detail.18 The patient had
mildly elevated antinuclear antibodies (1:320) and double-
stranded DNA antibodies (immunoglobulin G). Antibodies
against aquaporin-4 and extractable nuclear antigens were nega-
tive. At the time of the 7.0T MRI examination, she was treated
with methylprednisolone (4 mg daily) and methotrexate (15 mg
weekly) and was in clinical remission.
Neuropathologic examination. Three-micrometer sections
from formalin-fixed, paraffin-embedded tissue blocks were
stained with hematoxylin & eosin (H&E) and for CD45
(clone: 2B11&PD7/26 ventana-LCA, Ventana Medical
Systems, Tucson, AZ), CD3 (clone: 2GV6, Ventana Medical
Systems), CD4 (SP35, Ventana Medical Systems), CD8 (clone:
C8/144B, Dako, Glostrup, Denmark), CD20 (clone: cyL26,
Ventana Medical Systems), and neurofilament heavy-chain (NF
smi31, Affinity, Exeter, UK). Selected sections from brainstem
and insular cortex were double-stained for CD3 and NF.
Adjacent sections were stained for Luxol fast blue and H&E.
Adjacent formalin-fixed tissue section from brainstem tissue
(autopsy) as well as sections from 3 additional brainstem
biopsies were similarly stained for light-chain restriction (kappa-
smi and lambda-smi, smlg reaction, Dako), the zinc-finger
transcription factor, B-cell lymphoma 6 protein (Bcl-6, clone:
LN22 NovoCastra, Leica Biosystems, Newcastle, UK), the
large B-cell lymphoma marker, Multiple Myeloma Oncogene
1 (MUM-1, IRF4, Dako), and the precursor B lymphoma
marker, CD10 (clone: 56C6-CALLA, NovoCastra, Leica
Biosystems). All immunohistochemical stainings were performed
using the BenchMark Ultra IHC staining system (Ventana
Medical Systems). For detection, ultraView Universal DAB
Detection Kit was applied (Ventana Medical Systems).
Toluidine blue was used as counterstaining. Lymphoma
stainings were assessed by a skilled lymphoma pathologist.
Digital images were obtained at a magnification of 53 or
103 (brainstem) or 103 (cerebellum, parietal cortex,
insular cortex/basal ganglia, nerve root, and biopsies 1–3)
using a Leica microscope (Leica 4000B LED, Leica
Microsystems, Wetzlar, Germany) equipped with a Leica
digital camera (Leica DFC420, Leica Microsystems).
Ultra-high-field MRI data acquisition and postprocessing.
Ultra-high-field MRI were acquired using a 7.0T whole body MRI
scanner (Magnetom, Siemens, Erlangen, Germany) applying
a 24-channel receive head coil (Nova Medical, Wilmington,
MA) equipped with a birdcage volume coil used for
transmission. The imaging protocol included 2D T2*-
weighted (T2*W) fast low angle shot (echo time [TE] 5
25.0 ms, repetition time [TR] 5 1,820 ms, spatial resolution 5
0.2 3 0.2 3 2 mm3, supratentorial coverage), pregadolinium and
postgadolinium 3D T1-weighted magnetization-prepared
rapid gradient echo (T1W MPRAGE) (TE 5 2.98 ms,
TR 5 2,300 ms, inversion time 5 900 ms, spatial
resolution 5 1.0 3 1.0 3 1.0 mm3, whole brain coverage),
and 3D flow-compensated gradient echo–based susceptibility-
weighted imaging (SWI) (TE 5 14 ms, TR 5 25 ms, flip
angle 5 12°, spatial resolution 5 0.5 3 0.5 3 1.0 mm3,
supratentorial and infratentorial coverage). For infratentorial
imaging, postgadolinium volumetric interpolated brain
examination (VIBE) sequence was used (TE 5 3.3 ms,
TR 5 19.7 ms, spatial resolution 5 0.5 3 0.5 3 1.0 mm3).
To identify vascular structures within contrast-enhancing
CLIPPERS lesions, we calculated the sum of (1) coregistered
T1W MPRAGE with supratentorial T2*W images, and (2) cor-
egistered VIBE with infratentorial SWI images using the image
calculator function of the MIPAV software package (version
7.0.1, Bethesda, MD).
RESULTS Perivascular inflammation in CLIPPERS
extends to areas with normal appearance on 3.0T MRI:
Analysis of the autopsy case. First, we investigated
inflammation in different brain regions correspond-
ing to gadolinium-enhancing and normal-appearing
brain areas on 3.0T MRI (autopsy tissue of patient
1): brainstem and cerebellum were compared to
parietal and insular cortex (figure 1). Perivascular
accumulation of CD451 lymphocytes (figure 1,
B, G, L, and Q) with predominance of CD31
T cells (figure 1, C, H, M and R) and CD41
T cells were detected in brainstem and cerebellum
as expected (figure 1, D and N). CD41 T cells also
infiltrated the parenchyma, which was most
pronounced in the brainstem (figure 1D).
Accumulation and infiltration by CD81 T cells
were less pronounced (figure 1, E and Q), and
only a few CD201 B cells were observed in close
proximity to the vessel wall (figure 1, F and P).
However, insular and parietal cortex with normal
appearance on 3.0T MRI revealed a similar, albeit
less prominent perivascular accumulation of CD41
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T cells (figure 1, I and S), fewer CD81 T cells
(figure 1, J and T), and a very limited number of
CD201 B cells (figure 1, K and U). CD41 T cells
also infiltrated the parenchyma the insular cortex
(figure 1S). Perivascular inflammation was also
found in the roots of cranial nerves (figure 1,
V and W). These data suggested that brain areas
with normal appearance on 3.0T MRI may be
affected by inflammation in CLIPPERS syndrome.
No evidence of lymphoma and prelymphoma state:
Analysis of 4 cases. Next, brainstem samples (patients
1–4) were analyzed for the possibility of lymphoma
or prelymphoma. We found no evidence for mono-
clonal cell expansion using staining for light chain
restriction (figure 2, A–B, F–G, K–L, and P–Q)
and lymphoma markers CD10, Bcl-6, and MUM-1
(figure 2, C–E, H–J, M–O, and R–T). Follow-up of
the 3 biopsy cases (patients 2–4; mean of 75 months)
did not indicate clinical or paraclinical evidence of
lymphoma either.
Ultra-high-field MRI reveals perivascular lesions outside
the brainstem/cerebellum and tissue damage. Since path-
ologic examination indicated perivascular inflamma-
tion in brain areas with normal appearance on 3.0T
MRI, albeit less pronounced than in brainstem and
cerebellum, we next examined 2 patients with
CLIPPERS by 7.0T MRI during clinical remission.
Contrast-enhancing lesions (n 5 20) were only
depicted in patient 5. Of those, 2 lesions were
found in a supratentorial localization affecting (n 5
1) or bordering (n 5 1) the thalamus (figure 3D).
Cortical gray matter lesions were not observed on
supratentorial T2*W images.
To visualize the perivascular distribution of le-
sions, we fused contrast-enhanced T1W and supra-
tentorial T2*W images with a volume resolution
Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)
Immunohistochemical stainings for light chain restriction (lambda-smi and kappa-smi: A, B, F, G, K, L, P, and Q), CD10 (C, H, M, and R), Bcl-6 (D, I, N, and S), and
MUM-1 (E, J, O, and T) in samples from an autopsy (A–E) and biopsy specimens of 3 patients (F–J, K–O, and P–T). We found no evidence for light chain
restriction or significant staining for lymphomamarkers CD10, Bcl-6, or MUM-1 suggesting a prelymphoma or lymphoma state. Magnification 53 (A–E), 103
(F–T). Scale bar: 200 mm (A–E), 100 mm (F–T).
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of 0.08 mm3 to display small T2*W hypointense
venous structures within gadolinium-enhancing
hyperintense CLIPPERS lesions (figure 3). Indeed,
a distinct venous vessel could be seen within the
center of the thalamic CLIPPERS lesion in vivo
(figure 3C). Due to technical limitations, a different
approach with a lower spatial resolution of 0.25 mm3
was used for infratentorial areas. Even with this
approach, a very small venous vessel could be de-
picted within 8 of 10 contrast-enhancing CLIPPERS
lesions on fused postgadolinium VIBE and SWI (data
not shown).
In addition, 7.0T T1W MPRAGE depicted
numerous T1W hypointense lesions within the pons
and cerebellum (figure 4, E–G) in patient 5, which
were not visible on conventional 3.0T MRI (figure 4,
A–D), indicating severe tissue destruction within
postinflammatory CLIPPERS lesions (figure 4). Mul-
tiple pontine postinflammatory T1W hypointense le-
sions were also found in patient 6 by using T1W
imaging at 7.0T (data not shown). Corresponding
to the 7.0T MRI findings, neurofilament and myelin
staining revealed axonal injury and myelin loss in
brainstem areas with severe inflammation of the
autopsy case (figure 4, H and I). Preservation of axons
and myelin was seen in areas with limited inflamma-
tion (figure 4, J and K).
DISCUSSION In this article, we describe neuropath-
ologic as well as high-field/ultra-high-field MRI
features of 6 patients with CLIPPERS syndrome.
The diagnosis of CLIPPERS syndrome was supported
by (1) postcontrast T1-weighted MRI with typical
punctate, nodular, or curvilinear and occasionally
more confluent gadolinium-enhancing lesions, (2)
perivascular inflammation in the brainstem dominated
by T cells, (3) clinical course with several steroid-
responsive relapses, and (4) absence of other diseases.
In addition to punctate and curvilinear lesions, case 5
had a larger confluent lesion in the cerebellum.
Similar lesions were previously described in patients
with CLIPPERS2 and a biopsy of the cerebellar lesion
of case 5 demonstrated histopathologic features of
CLIPPERS.
We found widespread perivascular inflammation
in brain areas with normal appearance on 3.0T
MRI in an autopsy case of CLIPPERS syndrome.
The inflammatory pattern of these regions was similar
to the original1 and later neuropathologic descriptions
of the disease2,3 characterized by pronounced CD41
T-cell infiltration of brain tissue and less predominant
angiocentric CD81 T-cell and CD201 B-cell inflam-
mation. Although T2W and gadolinium-enhancing
lesions were found only in the pons, midbrain, and
cerebellar regions, inflammation could be seen as dis-
tant as the parietal cortex and even involved the cranial
nerve roots. The degree of inflammation, however,
showed a gradient of less inflammation with greater
distance from the primarily affected areas (brainstem
. cerebellum . insular cortex . parietal cortex),
suggesting that the inflammation seen on conventional
1.5T–3.0T MRI only depicts the most severely
Figure 3 Ultra-high-field MRI at 7.0T (patients 5 and 6)
Supratentorial T2*-weighted (A, B) and postgadolinium T1-weighted images (D) of patient 5 obtained at 7.0T are displayed.
Postgadolinium T1-weighted imaging depicts a small contrast-enhancing lesion (black arrow, D) that is only marginally
delineated on corresponding T2*-weighted images (zoom, B) despite using a very high spatial resolution of 0.08mm3. Fusion
(C) of coregistered postgadolinium T1-weighted (D) and T2*-weighted (B) identifies a small brain vessel within the center of
the chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) lesion
(white arrow, C). T2*w5 2D T2*-weighted fast low angle shot at 7.0T, echo time (TE)5 25.0ms, repetition time (TR)5 1,820
ms, spatial resolution5 0.23 0.23 2mm3; T1-gad5 postgadolinium 3D T1-weightedmagnetization-prepared rapid gradient
echo at 7.0T, TE 5 2.98 ms, TR 5 2,300 ms, inversion time 5 900 ms, spatial resolution 5 1.0 3 1.0 3 1.0 mm3.
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affected brain regions. Consistent with these neuro-
pathologic findings, cognitive impairment such as dys-
executive syndromes, language disturbance, frontal
release signs and cortical atrophy were described in
a case series of CLIPPERS syndrome, suggesting that
cortical involvement may be more prominent than
initially thought.2
Since our pathologic examinations revealed wide-
spread inflammatory changes in brain tissue appear-
ing normal on conventional 3.0T MRI, we
performed ultra-high-field 7.0T MRI in 2 additional
CLIPPERS cases to investigate such possibilities
in vivo. Indeed, these efforts revealed contrast-
enhancing lesions in supratentorial locations, sup-
porting widespread inflammation in brain areas, in
contrast to the only other autopsy report published
recently.19 The number of such contrast-enhancing
lesions was, however, limited, which is likely due to
the immunosuppressive treatment: MRI changes in
CLIPPERS respond rapidly to immunosuppres-
sion.1,3,20,21 Remarkably, when combining T1W and
supratentorial T2*W images with a resolution as
good as 0.08 mm3, we could show a vascular structure
within most contrast-enhancing lesions. The 7.0T
MRI thus enabled visualization of perivascular
inflammation, the neuropathologic hallmark of
CLIPPERS, in vivo. The hypointense appearance of
these intralesional vascular structures on T2*W and
SWI images indicates the presence of a paramagnetic
material. Thus, these intralesional vascular structures
are most likely small veins filled with paramagnetic
deoxyhemoglobin.22 A central intralesional vein was
previously reported to be a characteristic finding in
MS lesions.11,12,14,16 On the contrary, a central vein is
Figure 4 Comparison of 7.0T and 3.0T MRI (patients 5 and 6)
T1-weighted images of patient 5 at 3.0T and 7.0T are shown. Owing to substantially increased signal-to-noise ratio, 7.0T T1-weightedmagnetization-prepared
rapid gradient echo delineates numerous T1-weighted hypointense lesions within the pons and cerebellum (arrowheads, E–G). In contrast, corresponding areas
appear normal (C, D) or only marginally hypointense on T1-weighted images at 3.0T (circle, A, B). T1-weighted hypointensity within non-contrast-enhancing
chronic lymphocytic inflammationwith pontine perivascular enhancement responsive to steroids lesionsmay indicate postinflammatory structural brain damage
including axonal loss on top of demyelination. Immunohistochemical stainings of autopsy case for neurofilament (NF) revealed massive axonal injury in the
inflammatory lesion of the brainstem (H; CD3 red, NF brown) compared to insular cortex with limited inflammation (J). The presence of phosphorylated NF in the
perinuclear cytoplasm of neurons suggests retrograde neuronal degeneration due to axonal injury in the lesions (H). Similarly, severe loss of perivascular myelin
was found in areas of severe inflammation (I), compared to areas with limited inflammation (K), with Luxol fast blue and hematoxylin & eosin. 7.0T 5 3D
T1-weighted magnetization-prepared rapid gradient echo at 7.0T, echo time 5 2.98 ms, repetition time 5 2,300 ms, inversion time 5 900 ms, spatial
resolution 5 1.0 3 1.0 3 1.0 mm3; 3.0T 5 standard T1-weighted axial images (B–D) and T1-weighted magnetization-prepared rapid gradient echo at 3.0T
(A). 3.0T and 7.0T MRI examinations were performed 3 days apart. Magnification 103 (H–K). Scale bar 5 100 mm.
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only rarely depictable in brain lesions of other origin
such as neuromyelitis optica,14 cerebral small vessel
disease,23 and Susac syndrome,16 which is considered
a microangiopathy of the brain, cochlea, and ret-
ina.24–26 Evidence for the presence of MRI-
detectable intralesional veins in other inflammatory
vasculopathies such as Wegner granulomatosis, Beh-
çet syndrome, primary CNS vasculitis, and vasculitis
in systemic lupus erythematosus is, however, limited.
Of note, highly resolving imaging techniques were
needed to visualize the intralesional venous vessel in
CLIPPERS lesions, which thus appear much smaller
in diameter than central veins commonly visualized in
MS lesions on 7.0T T2*W images. However, as no
systematic analysis of vessel diameters in CLIPPERS
vs MS could be performed owing to the low sample
size, future comparative studies will have to investi-
gate whether this feature is consistently detectable in
other CLIPPERS cases and distinct from MS.
In addition, we utilized the higher sensitivity of
7.0T T1W MPRAGE vs T1W imaging at 1.5T15
and 3.0T27 to detect brain lesions and to investigate
brain areas that appeared normal at lower field
strengths. Although 1.5T–3.0T MRI and 7.0T
MRI were done at different time points, therefore
direct comparison was not possible, patients had no
signs of clinical activity at the time of the MRI
examinations. Ultra-high-field MRI revealed
numerous T1W hypointense lesions within the
pons and cerebellum in one of the patients, indi-
cating postinflammatory brain tissue destruction,
which were not visible on conventional 3.0T
MRI. Indeed, axonal injury with evidence of axonal
spheroids and torpedoes was found in our autopsy
case, similar to previous results.2,3 However, axonal
injury and myelin loss was observed only in areas
with severe inflammation, which may explain the
restricted localization of T1W hypointense lesions
on 7.0T MRI.
Since emerging cases of CLIPPERS with subse-
quent diagnosis of lymphoma have been recently
described,6–8 we investigated this possibility in the
autopsy case and available biopsy samples from 3
other Danish cases. We found no evidence for pre-
lymphoma or lymphoma when using immunohisto-
chemical staining for light chain restriction or
lymphoma markers CD10, Bcl-6, and MUM-1.
Since the analyses were done on the initial diagnostic
biopsies, this might not exclude per se that the pa-
tients progressed into a lymphoma. However, 3 of the
patients have been already followed for a mean of
more than 6 years without any evidence of lym-
phoma. Altogether, our present results strengthen
the concept that CLIPPERS is a distinct disease entity
that can be discerned from alternative diagnoses such
as lymphoma or vasculitis.
We found perivascular inflammation predomi-
nated by CD41 T cells even in areas with normal
appearance on 3.0TMRI and extending to the cranial
nerve roots, suggesting widespread inflammation in
CLIPPERS syndrome, though most prominent in the
primarily affected brainstem. We found no evidence
of lymphoma in our 4 investigated patients. When
applying ultra-high-field MRI at 7.0T, supratentorial
lesions could be confirmed, and most of the contrast-
enhancing lesions contained a vessel structure indicat-
ing the pathologic hallmark of CLIPPERS syndrome
in vivo. The 7.0T MRI also indicated prominent
T1W hypointensities suggesting tissue injury, which
could not be seen on 3.0T MRI but corresponded to
axonal injury and loss of myelin in the autopsy spec-
imen. One limitation of the study might be the appli-
cation of immunosuppressive treatment at the time of
biopsy or MRI examination (table 1).
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